Measuring microRNAs in blood may indicate dementia risk
Researchers identified three microRNAs whose levels were associated with mental performance in cells, mice and humans.
List view / Grid view
Researchers identified three microRNAs whose levels were associated with mental performance in cells, mice and humans.
Mission Therapeutics was granted $500,000 from the The Michael J Fox Foundation for Parkinson’s Research for DUB inhibitor testing.
Boosting dendritic cells prevented immunotherapy resistance in mouse models, suggesting a new approach to colorectal cancer therapies.
Researchers have used genetically engineered SARS-CoV-2 Spike proteins to boost antibodies against a range of coronaviruses in mice.
Gingiva-derived mesenchymal stem cells were used to surgically repair injured peripheral nerves, showing potential for new therapies.
Scientists have identified a subpopulation of mesenchymal stem cells with enhanced bone fracture healing and differentiation abilities.
A new study has suggested that mucosal vaccines may reduce transmission of airborne viruses such as COVID-19 more than injectable vaccines.
Landmark pre-clinical studies to investigate whether psychedelic derivatives can reduce alcohol consumption have been initiated.
Nanobubbles known as extracellular vesicles (EVs) were shown to deliver protein drugs in animal models with inflammatory diseases.
RGX-202 was found to foil a key pathway that cancer cells rely on for energy in mice, presenting a possible new colorectal cancer therapy.
Axitinib, a common chemotherapy drug, restored memory and cognitive function in mouse models, representing a potential Alzheimer’s treatment.
Researchers have created the first “living medicine” to treat antibiotic-resistant bacteria growing on the surfaces of medical implants.
A protein-based vaccine has proven a promising option to prevent rheumatoid arthritis, improving bone quality in animal models.
Psilera will participate in two studies with the National Institute on Drug Abuse to combat addiction using a novel DMT formulation.
An MIT study has used the first statistical model to finely characterise how ketamine anaesthesia affects the brain, possibly improving patient outcomes.